Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCARB1 | Q8WTV0 | 4/20 | 0.40 |
| ▸ | HTR6 | P50406 | 2/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | PARG | Q86W56 | 2/20 | 0.34 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | FNTB | P49356 | 1/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2027138 | 1.00 | SCARB1 (0.40) | SCARB1HTR6HRH1PARGFNTA | |
| SCHEMBL12579055 | 1.00 | SCARB1 (0.40) | SCARB1HTR6HRH1PARGFNTA | |
| SCHEMBL2025539 | 1.00 | SCARB1 (0.40) | SCARB1HTR6HRH1PARGFNTA | |
| SCHEMBL2026761 | 0.93 | SCARB1 (0.36) | SCARB1HTR6HRH1PARGFNTA | |
| SCHEMBL12579070 | 0.93 | SCARB1 (0.36) | SCARB1HTR6HRH1PARGFNTA | |
| SCHEMBL12579051 | 0.91 | HTR6 (0.36) | SCARB1HTR6HRH1PARGFNTA | |
| SCHEMBL2023590 | 0.91 | HTR6 (0.36) | SCARB1HTR6HRH1PARGFNTA | |
| SCHEMBL12579062 | 0.90 | HRH1 (0.36) | SCARB1HTR6HRH1PARGFNTA | |
| SCHEMBL12579057 | 0.88 | SCARB1 (0.36) | SCARB1HTR6HRH1PARGFNTA | |
| SCHEMBL2023139 | 0.88 | SCARB1 (0.36) | SCARB1HTR6HRH1PARGFNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094658-B1 | TETRAHYDROCYCLOPENTA[B]INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | LILLY CO ELI (US) | 2011-12-21 | — | — | EP | disclosed |
| US-7968587-B2 | Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100069404-A1 | TETRAHYDROCYCLOPENTA[b] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069404-A1 | TETRAHYDROCYCLOPENTA[b] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, NR5A1, MUSK | SCARB1 1045/4885HTR6 251/4885HRH1 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.